Mental Health DailyResearch. Evidence. Perspective.Published research on Antipsychotics.
Vraylar (Cariprazine), also sold under the name Reagila [in European countries], is an atypical antipsychotic developed by the pharmaceutical company Allergan. In 2015, Vraylar received FDA …
Read articleRexulti (Brexpiprazole), is an atypical antipsychotic that was jointly developed by pharmaceutical companies Otsuka and Lundbeck. In 2015, the FDA approved Rexulti for the treatment of schiz…
Read articleRexulti (Brexpiprazole), is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia and major depressive disorder (as an adjunct). The drug was engineered via collab…
Read articleSeroquel (Quetiapine) is an atypical antipsychotic engineered in the early 1990s by the pharmaceutical company AstraZeneca. It was first approved by the FDA in 1997 for the treatment of schi…
Read articleSeroquel (Quetiapine) is a medication that was developed by AstraZeneca from 1992 through 1996. It received FDA approval in 1997 for the treatment of schizophrenia, and has since received ap…
Read articleAbilify (Aripiprazole) is a medication that was developed by Otsuka Pharmaceuticals and approved by the FDA in 2002 for the treatment of schizophrenia. Approximately 2 years thereafter (in 2…
Read articleVraylar (Cariprazine) was approved by the FDA on September 17, 2015 for the treatment of schizophrenia and mania associated with bipolar disorder. In clinical trials, the drug was referenced…
Read article